Neurosterix adds Karuna veterans as it details $105m financing
Neurosterix named its Series B investors and added Andrew Miller and Stephen Brannan to senior roles.

A biotech financing becomes more informative when the investors and clinical-development team are visible. Neurosterix has added that detail.
What happened
On 12 November, Neurosterix identified RTW Investments as lead investor in its $105m Series B and named participants including GV and Janus Henderson. It also appointed Karuna founder Andrew Miller as executive chair and Stephen Brannan as clinical advisory board chair. Addex had disclosed the financing on 11 November. Funding supports Phase 2 development of NTX-253 for schizophrenia.
Why it matters
The appointments bring neuropsychiatric drug-development experience into roles that can influence study design and development strategy. Naming the investors adds information about the specialist capital supporting the programme.
The bigger picture
Biotech progress depends on capital, clinical planning and experienced teams working together. Here, the new development is the expanded investor and leadership disclosure around an existing financing.
